October 2024
Case
HBS Case Collection

Allurion: Competing in the Age of GLP-1

By: Satish Tadikonda, Rajiv Lal, David Lane and Sarah Sasso

Format:Print
| Language:English
| Pages:27

Abstract

Shantanu Gaur had built Allurion into a formidable business internationally, providing obesity patients with a less invasive option long before GLP-1 drugs became the latest craze. Selling Allurion's medical device across 60+ countries, he awaited FDA approval to bring his technology to patients in the US. As time ticked by, GLP-1 drugs came like a tsunami, seemingly conquering the weight-loss market. With approval seemingly coming soon, Gaur had to decide what his strategy should be in continuing to grow Allurion, dealing with the challenges of the GLP-1 craze, and preparing for long term success.

Keywords

Corporate Entrepreneurship; Health Care and Treatment; Global Strategy; Competitive Strategy; Medical Devices and Supplies Industry; Health Industry; United States; United Kingdom; France; India; Brazil; Middle East

Citation

Tadikonda, Satish, Rajiv Lal, David Lane, and Sarah Sasso. "Allurion: Competing in the Age of GLP-1." Harvard Business School Case 525-011, October 2024.